ERBB2 and breast cancer: Well-known examples include the HER2-directed mAbs, their derivatives conjugated with chemotherapeutic or immunotherapeutic drugs (44), and mAbs that target the vascular endothelial growth factor (VEGF) (45) for breast cancer treatment.